Effect of fluoroscopic guided single needle trans-discal approach for celiac plexus block in patients with upper gastrointestinal tumours on pain relief; one year follow up

Recruiting

• Conditions: upper gastrointestinal cancer pain; Anaesthesiology - Pain management; Cancer - Other cancer types

• Registration Number: ACTRN12615000346572
• Lead Sponsor: Tanta University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1- Thirty patients have inoperable upper gastrointestinal tumors including (cancer lower third esophagus, stomach, pancreas, biliary tract).
2- With uncontrolled visceral pain (Visual analogue scale greater than or equal to 7/10).
3- With maximum tolerable dose of opioids.

Exclusion Criteria

1-Patients have coagulopathy.
2- Patients have local infection at the area of needle insertion.
3- Decompensate cardiac disorders.
4- Hemodynamic instability.
5- Radiological evident metastatic lesions.
6- Psychiatric disorders affecting cooperation.
7- Has undergone previous blocks affecting severity of the present pain.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
pper gastrointestinal cancer pain as assessed using Visual Analogue Scale (VAS 0 - 10)[patients will be evaluated personally in pain clinic every two weeks and by telephone every week (to evaluate patient generally and if there is any need for early date as incidence of severe pain, change character of pain or side effects). Pain intensity will be determined by asking the patients to record the scale (VAS) daily on a paper given to them from the clinic and the observer will calculate the average weekly. However, data will be included in statistical analysis at preprocedure, then every 2 weeks for 4 months and then monthly for one year]

Secondary Outcome Measures

Name	Time	Method
Opioid consumption during the follow up period by patient self-report and pain physician report[data will be included in statistical analysis every 2 weeks for 4 months and then monthly for one year after the procedure. ];opioids side effects, including loss of appetite, nausea or vomiting, insomnia, constipation, urinary retention, pruritis will be evaluated and subjectively determined by each patient. Incidence of side effects as will be informed by the patient and if it will be find moderate to severe degree and require medications, changing opioid regimen or tapering the dose down, it will be reported in the results [during the follow up period, i.e. up to 1 year post procedure]